They identified KIF11 inhibitor (originally indicated for several types of cancers), GSK3B inhibitor (originally indicated for several types of cancers), and AP-1 inhibitor (originally indicated for RA) as potential candidates for a repurposed treatment of T2D. This evidence concerns the gene GSK3B and cancer.